Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors

References

• Blume-JensenPHunterTOncogenic kinase signallingNature2001411683535536511357143
   PubMed Web of Science ®Google Scholar
• DrilonASienaSOuSISafety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two Phase I trials (ALKA-372-001 and STARTRK-1)Cancer Discov20177440040928183697
   PubMed Web of Science ®Google Scholar
• BrodeurGMMinturnJEHoRTrk receptor expression and inhibition in neuroblastomasClin Cancer Res200915103244325019417027
   PubMed Web of Science ®Google Scholar
• AisnerDLNguyenTTPaskulinDDROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular driversMol Cancer Res201412111111824296758
   PubMed Web of Science ®Google Scholar
• BergethonKShawATOuSHROS1 rearrangements define a unique molecular class of lung cancersJ Clin Oncol201230886387022215748
   PubMed Web of Science ®Google Scholar
• MalikSMMaherVEBijwaardKEU.S. Food and Drug Admin-istration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positiveClin Cancer Res20142082029203424573551
   PubMed Web of Science ®Google Scholar
• ShawATGandhiLGadgeelSAlectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multi-centre, phase 2 trialLancet Oncol201617223424226708155
   PubMed Web of Science ®Google Scholar
• OuSHAhnJSDe PetrisLAlectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a Phase II global studyJ Clin Oncol201634766166826598747
   PubMed Web of Science ®Google Scholar
• KhozinSBlumenthalGMZhangLFDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancerClin Cancer Res201521112436243925754348
   PubMed Web of Science ®Google Scholar
• ShawATOuSHBangYJCrizotinib in ROS1-rearranged non-small-cell lung cancerN Engl J Med2014371211963197125264305
   PubMed Web of Science ®Google Scholar
• FDA expands use of Xalkori to treat rare form of advanced non-small cell lung cancer [press release]2016 Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm490329.htmAccessed June 26, 2018
   Google Scholar
• SniderWDFunctions of the neurotrophins during nervous system development: what the knockouts are teaching usCell19947756276388205613
   PubMed Web of Science ®Google Scholar
• AmatuASartore-BianchiASienaSNTRK gene fusions as novel targets of cancer therapy across multiple tumour typesESMO Open201612e00002327843590
   PubMed Web of Science ®Google Scholar
• VaishnaviACapellettiMLeATOncogenic and drug-sensitive NTRK1 rearrangements in lung cancerNat Med201319111469147224162815
   PubMed Web of Science ®Google Scholar
• DoganSWangLPtashkinRNMammary analog secretory carcinoma of the thyroid gland: a primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusionMod Pathol201629998599527282352
   PubMed Web of Science ®Google Scholar
• ArdiniEMenichincheriMBanfiPEntrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer IndicationsMol Cancer Ther201615462863926939704
   PubMed Web of Science ®Google Scholar
• ArdiniELombardi BorgiaADe PontiCIdentification and preclinical characterization of NMS-P626, a potent, selective and orally bioavailable TrkA inhibitor with anti-tumor activity in a TrkA-dependent colorectal cancer. 22nd AACR-NCI-EORTC symposium on molecular targets and cancer therapeuticsEur J Cancer Supplements2010873940
   Web of Science ®Google Scholar
• MenichincheriMArdiniEMagnaghiPDiscovery of entrectinib: a new 3-Aminoindazole as a potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitorJ Med Chem20165973392340827003761
   PubMed Web of Science ®Google Scholar
• ArdiniEMenichincheriMBanfiPIn vitro and in vivo activity of NMSE-628 against ALK mutations resistant to XalkoriMol Cancer Ther201110Suppl 1
   Google Scholar
• AndersonDCiomeiMBanfiPInhibition of Trk-driven tumors by the pan-Trk inhibitor RXDX-101EJC201450Supplement 6101
   Google Scholar
• ArdiniEMenichincheriMBanfiPThe ALK inhibitor NMS-E628 also potentially inhibits ROS1 and induces tumor regression in ROS-driven modelsCancer Res J2013788 Supplement2092
   Google Scholar
• ArevaloJCCondeBHempsteadBIChaoMVMartin-ZancaDPerezPA novel mutation within the extracellular domain of TrkA causes constitutive receptor activationOncogene200120101229123411313867
   PubMed Web of Science ®Google Scholar
• CrowleyCSpencerSDNishimuraMCMice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neuronsCell1994766100110118137419
   PubMed Web of Science ®Google Scholar
• SkaperSDThe biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptorsCNS Neurol Disord Drug Targets200871466218289031
   PubMed Web of Science ®Google Scholar
• Myung-Ju AhnBCCSienaSDrilonAEntrectinib in patients with locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC)IASLC 18th World Conference on Lung Cancer2017Yokohama, Japan
   Google Scholar
• RangarajuSLiGChristiansenJHornbyZMultaniPEsquibelVManevalECTRTH-10. Pediatric Phase 1/1B Study of entrectinib in patients with primary brain tumors, neuroblastoma, and NTRK, ROS1, or ALK FusionsNeuro-Oncology2017194iv53
   Google Scholar
• Ignyta Receives FDA Orphan Drug Designation for Entrectinib for Treatment of NTRK Fusion-Positive Solid Tumors [press release]2017 Available from: https://www.businesswire.com/news/home/20170710005477/en/Accessed June 26, 2018
   Google Scholar
• Ignyta Receives European Medicines Agency Prime Designation for Entrectinib in NTRK Fusion-Positive Solid Tumors [press release]2017 Available from: https://www.businesswire.com/news/home/20171017005620/en/Ignyta-Receives-European-Medicines-Agency-Prime-DesignationAccessed June 26, 2018
   Google Scholar
• Ignyta Receives Orphan Drug Designation and Rare Pediatric Disease Designation from FDA for Entrectinib for the Treatment of Neuroblastoma [press release]2014 Available from: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM508677.pdfAccessed June 26, 2018
   Google Scholar
• RussoMMisaleSWeiGAcquired resistance to the TRK inhibitor entrectinib in colorectal cancerCancer Discov201661364426546295
   PubMed Web of Science ®Google Scholar
• DrilonALiGDoganSWhat hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)Ann Oncol201627592092626884591
   PubMed Web of Science ®Google Scholar
• CuiJJZhaiDDengWTPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants28 EORTC – NCI – AACR Symposium on Molecular Targets and Cancer Therapeutics 2016Munich, Germany
   Google Scholar
• DrilonANagasubramanianRBlakeJFA next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumorsCancer Discov20177996397228578312
   PubMed Web of Science ®Google Scholar
• HymanDMLaetschTWKummarSThe efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancersJ Clin Oncol20173518_suppl
   Web of Science ®Google Scholar
• LimSMKimHRLeeJSOpen-label, multicenter, Phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangementJ Clin Oncol201735232613261828520527
   PubMed Web of Science ®Google Scholar
• Alexander DrilonKKSLiuSVChoBCSTARTRK-2: A global phase 2, open-label, basket study of entrectinib in patients with locally advanced or metastatic solid tumors harboring TRK, ROS1, or ALK gene fusionsAACR Annual Meeting 2017April 1–5, 20172017Washington, DC
   Google Scholar